SUCCESSFUL USE OF COVID-19 CONVALESCENT PLASMA IN A PATIENT WITH MULTIPLE MYELOMA CHEMOTHERAPY

Abstract

Multiple myeloma (MM) is a clonal disease derived from plasma cells, whose biology and treatment can produce immunosuppression, which could explain the high mortality rate of patients with MM and COVID-19. The following describes the clinical course of a 63-year-old patient with arterial hypertension, type 2 diabetes mellitus, relapsed MM receiving chemotherapy and SARS-CoV-2 infection who presented a rapid deterioration of respiratory function, requiring orotracheal intubation and admission to the Intensive Care Unit of the HRLBO. Due to the progressive worsening of ventilatory parameters, and considering the different risk factors, it was decided to administer 200 cc of convalescent plasma, showing clinical improvement 24 hours after infusion; finally, the patient was extubated and transferred to the Intermediate Care Unit where she was subsequently discharged.